Nachrichten zur Royalty Pharma PLC Aktie

Royalty Pharma Declares Second Quarter 2025 Dividend

NEW YORK, April 21, 2025 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX)…

Royalty Pharma to Present at TD Cowen’s 45th Annual Health Care Conference

NEW YORK, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will…

Heres What Key Metrics Tell Us About Royalty Pharma (RPRX) Q4 Earnings

The headline numbers for Royalty Pharma (RPRX) give insight into how the company performed in the quarter ended December 2024,…

Royalty Pharma reports Q4 results

…

Royalty Pharma Reports Q4 and Full Year 2024 Results

NEW YORK, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for…

Royalty Pharma stock rises following RP Management buyout and $3 billion buyback plan By Investing.com

Royalty Pharma stock rises following RP Management buyout and $3 billion buyback plan…

Royalty Pharma Announces Transformative Step in Company’s Evolution With Acquisition of its External Manager and $3 Billion Share Repurchase Program

NEW YORK, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced two major steps…

Royalty Pharma Announces Dividend Increase

NEW YORK, Jan. 09, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that its board…

3 High-Yield Dividend Stocks to Buy in 2025 and Hold for a Decade or Longer

The benchmark S&P 500 index keeps reaching new highs, but not all of its components have participated in the rally.…

2 Exceptional Dividend Stocks Near 52-Week Lows You Could Regret Not Buying on the Dips

The benchmark stock indexes keep climbing to new heights, but there are plenty of attractive wallflowers at this dance. A…

3 High-Yield Dividend Growth Stocks to Buy in December and Hold for a Decade or Longer

Its been a great couple of years for the stock market. From the end of 2022 through Nov. 29, the…

Royalty Pharma to Present at Upcoming Investor Conferences

NEW YORK, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will…

Undercovered Dozen: Aurora Cannabis, FREYR Battery, Royalty Pharma, Talos Energy +

…

3 High-Yield Dividend Stocks You Can Buy With $130 Now and Hold at Least a Decade

This has been an amazing year for stocks. From the end of 2023 through Nov. 12, the benchmark S&P 500…

Royalty Pharma: Massive Opportunity Ahead

…

Royalty Pharma Reports Third Quarter 2024 Results

NEW YORK, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for…

Royalty Pharma to Announce Third Quarter 2024 Financial Results on November 6, 2024

NEW YORK, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will…

Royalty Pharma Declares Fourth Quarter 2024 Dividend

NEW YORK, Oct. 11, 2024 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX)…

Brain Biotech und der 128-Millionen-Euro-Deal - der "Big Deal" hat sein "Kleingedrucktes"

Brain Biotech verkauft ihre Lizenzrechte an dem Wirkstoff-Projekt Deucrictibant an Royalty Pharma. Den Erlös beziffert die Gesellschaft auf bis zu…

EQS-Adhoc: BRAIN Biotech AG schließt eine Vereinbarung über die Monetarisierung von Lizenzgebühren in Höhe von bis zu 128,88 Mio. EUR für den investigativen Pharmawirkstoff Deucrictibant mit Royalty Pharma ab (deutsch)

BRAIN Biotech AG schließt eine Vereinbarung über die Monetarisierung von Lizenzgebühren in Höhe von bis zu 128,88 Mio. EUR für…

Royalty Pharma and Ascendis Pharma Enter Into $150 Million Royalty Funding Agreement

Proceeds to support continued development and commercialization of Endocrine Rare Disease products, including the Yorvipath U.S. commercial launch, and general…

Ascendis Pharma and Royalty Pharma Enter into $150 Million Royalty Funding Agreement

Proceeds to support continued development and commercialization of Endocrine Rare Disease products, including the YORVIPATH® U.S. commercial launch, and general…

Royalty Pharma plc Q2: Beat And Raise Reaffirm Our Buy Rating

…

Royalty Pharma plc (RPRX) Q2 2024 Earnings Call Transcript

…

Royalty Pharma Declares Third Quarter 2024 Dividend

NEW YORK, July 17, 2024 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX)…

Royalty Pharma Announces Pricing of $1.5 Billion of Senior Unsecured Notes

NEW YORK, June 03, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) announced today that it has…

Royalty Pharma plc (NASDAQ:RPRX) Stocks Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?

It is hard to get excited after looking at Royalty Pharmas (NASDAQ:RPRX) recent performance, when its stock has...…